S&P 5007,713▲ 0.28%Nasdaq26,425▼ 0.02%Dow Jones52,496▲ 1.02%Nasdaq 10029,490▼ 0.13%VIX17.31▼ 6.13%US Dollar101.73▼ 0.25%Gold spot4,145▲ 0.30%WTI spot101.91▲ 1.04%
Sao Paulo Exchange · Brazil · Updated after 15 Oct 2026 close

BioMarin Pharmaceutical Inc.

B1MR34 · Sao Paulo Exchange · prices in BRL
BRL 144.05▲ +4.47 (3.20%)
Research reportHistorical data

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical is a biotechnology company that develops and markets medicines for rare genetic disorders. Its treatments address conditions such as phenylketonuria, certain mucopolysaccharidoses and achondroplasia, and it also produces enzyme replacement therapies. The company serves patients and specialist physicians through hospitals and treatment centres, and it is based in San Rafael, California, in the United States.

BioMarin Pharmaceutical Inc. is represented on the Sao Paulo Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code B1MR34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

50/ 100
Market X-Ray · price-based
Fair price profile
Ranks #752 of 1454 on the Sao Paulo Exchange · confidence High
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for Brazil yet.
TrendFair
54/100
Mixed trend against its averages.
See the numbers →
Above 200-day average-4.9%
From 52-week high-16.2%
MomentumFair
53/100
Typical recent returns for this exchange.
See the numbers →
3-month return-3.6%
6-month return3.3%
12-month, skipping last month15.3%
Stability (higher is calmer)Fair
59/100
Typical risk for this exchange.
See the numbers →
Volatility, 1 year (lower is calmer)34.7%
Worst drawdown, 1 year (smaller is calmer)-28.2%
LiquidityWeak
26/100
Thinly traded: prices can jump and exits can be hard.
See the numbers →
Avg daily value traded0.01M BRL
Zero-volume days63.3%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for Brazil when fundamentals data for this market is added. All Brazil stocks.
Price trend
Below its 200-day average
Versus its 50- and 200-day averages
52-week range
123.51 – 174.41
Price is 40% of the way up
Returns
−3.6% 3m · +0.2% 1y
Price returns, dividends not included
RSI (14)
30
Neutral zone

Price chart

52-wk range 123.51 – 174.41 Daily closes, split-adjusted

Signals

50-day average161.46
200-day average151.43
Golden/death cross (60d)Golden, 42 days ago
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)1.55

Technical summary

Daily
Strongly bearish
1 bullish · 4 neutral · 11 bearish
Weekly
Strongly bearish
1 bullish · 1 neutral · 10 bearish
Monthly
Strongly bearish
1 bullish · 1 neutral · 6 bearish
Moving averages (daily)
SMA 10143.2Bullish
EMA 10144.5Bearish
SMA 20151.2Bearish
EMA 20149.4Bearish
SMA 50161.5Bearish
EMA 50154.6Bearish
SMA 100152.8Bearish
EMA 100153.8Bearish
SMA 200151.4Bearish
EMA 200153.5Bearish
Oscillators (daily)
RSI (14)30.44Neutral
MACD (12, 26)-5.93Bearish
Momentum (12)-7.42Bearish
Stochastic %K (14)26.42Neutral
Williams %R (14)-73.58Neutral
CCI (20)-56.85Neutral
Pivot points (classic, last session)
S3
144.1
S2
144.1
S1
144.1
Pivot
144.1
R1
144.1
R2
144.1
R3
144.1
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.

Prices are end-of-day closes in BRL. Educational only, not financial advice.